港通医疗
(301515)
| 流通市值：15.51亿 | | | 总市值：23.66亿 |
| 流通股本：6557.06万 | | | 总股本：1.00亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 50,485,892.96 | 721,613,692.59 | 344,363,431.23 | 265,246,991.85 |
| 营业收入 | 50,485,892.96 | 721,613,692.59 | 344,363,431.23 | 265,246,991.85 |
| 二、营业总成本 | 62,319,573.87 | 665,991,785.18 | 342,076,025.87 | 258,173,556.45 |
| 营业成本 | 42,126,661.89 | 558,118,545.8 | 267,049,285.19 | 206,648,422.61 |
| 税金及附加 | 642,844.88 | 5,816,419.02 | 3,692,053.17 | 2,683,194.45 |
| 销售费用 | 6,352,457.73 | 38,901,382.51 | 29,855,978.36 | 20,990,861.34 |
| 管理费用 | 9,162,878.79 | 36,446,449.25 | 26,554,651.14 | 17,660,531.42 |
| 研发费用 | 3,804,100.75 | 25,993,152.8 | 14,381,647.71 | 9,908,545.53 |
| 财务费用 | 230,629.83 | 715,835.8 | 542,410.3 | 282,001.1 |
| 其中:利息费用 | 1,503,566.55 | 6,347,296.02 | 4,771,565.03 | 3,103,833.89 |
| 其中:利息收入 | 1,457,388.4 | 6,297,553.95 | 4,579,309.09 | 3,201,679.11 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 511,856.85 | 511,856.85 |
| 加:投资收益 | - | 200,049.07 | -179,385.42 | -46,749.16 |
| 资产处置收益 | 41,557.7 | 142,830.32 | 114,157.19 | 114,157.19 |
| 资产减值损失(新) | -134,614.23 | -4,456,420.43 | -1,614,316.75 | -1,525,575.51 |
| 信用减值损失(新) | 9,716,221.28 | -65,544,214.61 | -19,080,939.17 | -19,743,183.35 |
| 其他收益 | 411,595.12 | 4,832,667.87 | 2,219,863.32 | 1,340,034.61 |
| 四、营业利润 | -1,798,921.04 | -9,203,180.37 | -15,741,358.62 | -12,276,023.97 |
| 加:营业外收入 | 22,798.11 | 963,995.16 | 404,915.31 | 347,786.33 |
| 减:营业外支出 | 14,372.15 | 460,892.02 | 116,484.05 | 111,641.17 |
| 五、利润总额 | -1,790,495.08 | -8,700,077.23 | -15,452,927.36 | -12,039,878.81 |
| 减:所得税费用 | -305,726.71 | -3,521,294.29 | -3,616,309.55 | -2,898,420.2 |
| 六、净利润 | -1,484,768.37 | -5,178,782.94 | -11,836,617.81 | -9,141,458.61 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -1,484,768.37 | -5,178,782.94 | -11,836,617.81 | -9,141,458.61 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -662,873.3 | -2,645,330.24 | -10,208,398.36 | -8,404,410.35 |
| 少数股东损益 | -821,895.07 | -2,533,452.7 | -1,628,219.45 | -737,048.26 |
| 扣除非经常损益后的净利润 | -1,478,586.35 | -10,005,872.6 | -12,865,150.31 | -10,269,336.53 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | -0.03 | -0.11 | -0.09 |
| (二)稀释每股收益 | -0.01 | -0.03 | -0.11 | -0.09 |
| 八、其他综合收益 | - | -89,274.2 | -97,891.78 | -114,944.65 |
| 归属于母公司股东的其他综合收益 | - | -89,274.2 | -97,891.78 | -114,944.65 |
| 九、综合收益总额 | -1,484,768.37 | -5,268,057.14 | -11,934,509.59 | -9,256,403.26 |
| 归属于母公司股东的综合收益总额 | -662,873.3 | -2,734,604.44 | -10,306,290.14 | -8,519,355 |
| 归属于少数股东的综合收益总额 | -821,895.07 | -2,533,452.7 | -1,628,219.45 | -737,048.26 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-30 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |